Hepalink
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A leading Chinese biopharma company with a vertically integrated heparin business, CDMO services for biologics, and an innovative drug pipeline.
Cardiovascular
Technology Platform
Vertically integrated platform for heparin API production and purification, and a CDMO platform for recombinant biomacromolecules and gene therapy products.
Opportunities
Growth opportunities include expanding its high-margin CDMO business globally, advancing its innovative drug pipeline to commercialization, and leveraging its integrated heparin supply chain for new derivative products.
Risk Factors
Key risks include supply chain and quality control vulnerabilities in the heparin business, intense competition in the biologics CDMO sector, and clinical/regulatory failure of its innovative drug candidates.
Competitive Landscape
In heparin, it competes with companies like Pfizer and Sanofi, differentiated by vertical integration. In CDMO, it competes with Lonza and Samsung Biologics, leveraging cost-competitive Chinese manufacturing and acquired US expertise via Cytovance.